Bod Australia receives early green light to commence cannabis clinical trial

Bod Australia ASX BDA cannabis clinical trial approval

Cosmetics and natural medicines company Bod Australia (ASX: BDA) has surprised the market by announcing that it has secured ethics approval in a record time of 6 weeks from the Human Research Ethics Committee (HREC) in Australia.

The HREC has granted Bod Australia full ethics approval to begin cannabis phase I clinical trials, a step that can take as long as 12 months or more, depending on the nature of the proposal.

The trial which will determine the safety, tolerability and pharmacokinetics of its proprietary ‘ECs315’ CBD extract, with the extracts being administered as a single or multiple sublingual

... read more at: